Trastuzumab Suppliers USA
Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
Product | Description | |
---|---|---|
Trastuzumab Quick inquiry Where to buy Suppliers range | Trastuzumab. Group: Main Products. Grades: 96%. CAS No. 180288-69-1. Product ID: ACM180288691. Molecular formula: ClH. Mole weight: 36.46094;g/mol. IUPAC Name: chlorane. EC Number: 231-595-7. | |
Trastuzumab Quick inquiry Where to buy Suppliers range | Trastuzumab is a monoclonal antibody drug for the treatment of breast cancer which is HER2 receptor positive. It acts via binding to HER2 receptor to suppress cell duplication. Uses: The treatment of her2 receptor positive breast cancer. Synonyms: Herceptin; RhuMab HER2; Anti HER2, Ig gamma-1 chain C region; Recombinant humanized anti-HER2 antibody; IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer. CAS No. 180288-69-1. Molecular formula: C10H14N6O5. Mole weight: 145kda. | |
Trastuzumab Quick inquiry Where to buy Suppliers range | Trastuzumab Inhibitor. Uses: Scientific use. Product Category: T9912. CAS No. 180288-69-1. | |
Trastuzumab emtansine Quick inquiry Where to buy Suppliers range | Trastuzumab emtansine is an antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surface surfaces. Upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers. Grades: 95%. CAS No. 1018448-65-1. Molecular formula: C6448H9948N1720O2012S44· (C47H62ClN4O13S)n. | |
Deruxtecan Quick inquiry Where to buy Suppliers range | Deruxtecan analog is a drug-linker conjugate for antibody-drug conjugate (ADC). Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody-drug conjugate. DS-8201a significantly suppressed tumor growth in an immunocompetent mouse model with human HER2-expressing CT26.WT (CT26.WThHER2) cells. DS-8201a is currently in clinical trials. Synonyms: Deruxtecan Analog; Deruxtecan, Trastuzumab deruxtecan; DS-8201a; DS8201a; DS 8201a; Exatecan derivative; DX-8951 derivative; DX 8951; DX8951; N-[6-(2, 5-Dioxo-2, 5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S, 9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10, 13-dioxo-2, 3, 9, 10, 13, 15-hexahydro-1H, 12H-benzo[de]pyrano[3', 4':6, 7]indolizino[1, 2-b]quinolin-1-yl]amino}-2-oxoethoxy)methyl]glycinamide. Grades: ≥95%. CAS No. 1599440-13-7. Molecular formula: C52H56FN9O13. Mole weight: 1034.05. | |
GDC-0941 dimethanesulfonate Quick inquiry Where to buy Suppliers range | GDC-0941 dimethanesulfonate is a potent inhibitor of PI3Kα/δ with modest selectivity against p110β and p110&gamma. It is a novel selective class I phosphatidylinositol-3-kinase (PI3K) inhibitor. It is designed to bind the ATP-binding pocket of PI3K and to prevent formation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), a second messenger that transmits PI3K downstream signals. It causes growth inhibition in a variety of cancer cell lines, including A2780, MDA-MB-361, PC3, and U87MG. It also inhibits the growth of trastuzumab-sensitive and -resistant HER2-amplied cancer cells which harbor p110( mutations or PTEN loss. It also reduces tumor volume in different xenograft models. Synonyms: GDC-0941 dimethanesulfonate; GDC 0941 dimethanesulfonate; GDC0941 dimethanesulfonate; Pictilisib dimethanesulfonate; GDC-0941 (2 MeSO3H salt). Grades: >98%. CAS No. 957054-33-0. Molecular formula: C25H35N7O9S4. Mole weight: 705.85. | |
GDC-0941, Free Base, PI3K Inhibitor Quick inquiry Where to buy Suppliers range | GDC-0941 is a potent inhibitor of p110a and p110d (IC?? = 3nM). It selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway.GDC-0941 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. Folkes, A.J., et al. "The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer." J. Med. Chem. 51: 5522-5532 (2008).GDC-0941 inhibited the growth of >70% of breast cancer cell lines tested, with EC50's <1 µM. GDC-0941 also demonstrated antitumor activity in preclinical models of breast cancer. Yao, E., et al. "Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab." Clin. Cancer Res. 15: 4147-4156 (2009).The combination of GDC-0941 with trastuzumab is highly efficacious in the treatment of cancer cells in vitro and tumors in vivo. GDC-0941 also has antitumor activity in the treatment of trastuzumab-resistant cells and tumors. Junttila, T.T., et al. "Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941." Cancer Cell 15: 429-440 (2009).GDC-0941 inhibits the activity of recombinant PI3K in vitro with IC50's of 0.003 µM (P110α), 0.033 µM (P110 β), 0.003 µM (P110δ), 0.075 µM (P110γ), 0.58 µM (mTOR) and 1.23 µM (DNA-PK). GDC-0941 inhibited the growth of tumor cells in vitro with IC50's of 0.95 µM (U87MG), 0.07 µM (IGROV-1), 0.15 µM (DETROIT 562), 0.28 µM (PC3) and 0.54 µM (SKOV-3). GDC-0941 also inhibited the growth of U87 MG glioblastoma xenografts and IGROV-1 ovarian cancer xenografts in mice. Raynaud, F.I., et al. "Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941." Mol. Cancer Ther. 8: 1725-1738 (2009). Group: Biochemicals. Alternative Names: 2- (1H-indazol-4-yl) -6- ( (4- (methylsulfonyl) piperazin-1-yl) methyl) -4-morpholinothieno[3, 2-d]pyrimidine; 4-[2- (1H-Indazol-4-yl) -6-[[4- (methylsulfonyl) piperazin-1-yl]methyl]thieno[3, 2-d]pyrimidin-4-yl]morpholine; GDC 0941; GDC 941; GNE 0941; Pictilisib; Pictrelisib. Grades: Highly Purified. CAS No. 957054-30-7. Pack Sizes: 25mg, 50mg, 100mg. Molecular Formula: C??H??N?O?S?, Molecular Weight: 513.64. US Biological Life Sciences. | Worldwide |
Herzuma Quick inquiry Where to buy Suppliers range | Herzuma is a biosimilar of trastuzumab approved by EU for the treatment of patients with early breast cancer, metastatic breast cancer or metastatic gastric cancer whose tumors have either receptor tyrosine-protein kinase erbB-2 (HER2) overexpression or HER2 gene amplification. Uses: Cancer therapy. | |
N-Methyl-L-alanine hydrochloride Quick inquiry Where to buy Suppliers range | N-Methyl-L-alanine is a reactant used in the preparation of site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity. Synonyms: N-Me-L-Ala-OH HCl; N-Methyl-L-alanine; (2S)-2-(methylamino)propanoic acid. Grades: ≥ 98% (TLC). CAS No. 3913-67-5. Molecular formula: C4H9NO2·HCl. Mole weight: 139.62. |